EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Recombinant Type III Humanized Collagen Solution for Injection Promotes Skin Repair in Chinese Population: A Case Series

Xiaoguang Duan, Chunmei Ding, Jiewei Wu, Weiwei Bao, Yu Gao, Fei Liu, Wei Cai

Journal of Cosmetic Dermatology · 2025

DOI: 10.1111/jocd.70226 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Xiaoguang Duan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic Surgery, Chingho Medical Center, Shanghai, China. Hauptthemen laut MEDLINE: Acne Vulgaris, Erythema, Cicatrix, Hyperpigmentation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Funding by L'Oreal China was provided exclusively for the in vitro testing described in this article..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Facial erythema and acne scarring are common skin conditions that significantly impair quality of life, necessitating effective treatment options, particularly in Asian populations.

Aims

To evaluate the efficacy and safety of intradermal injections of recombinant type III humanized collagen (RhCol‐III) solution for alleviating facial erythema, improving skin texture associated with acne scarring, and evening out skin tone issues associated with post‐inflammatory hyperpigmentation (PIH) from acne while also searching for potential underlying anti‐inflammatory mechanisms of the RhCol‐III solution.

Methods

This case series included six Chinese participants with Fitzpatrick phototypes III/IV, presenting with facial erythema and/or acne scarring. Participants received intradermal injections of 2 mg/mL RhCol‐III solution at baseline, 30‐ and 60‐ days post‐baseline. Clinical evaluations were conducted using VISIA photography and self‐assessed Global Aesthetic Improvement Scale (GAIS) scores. Additionally, in vitro testing was performed using the U937 cell line with lipopolysaccharide (LPS) induction to assess the anti‐inflammatory effects of the RhCol‐III solution on tumor necrosis factor‐alpha (TNF‐α) and interleukin‐6 (IL‐6) secretion.

Results

All participants demonstrated a reduction in facial erythema post‐treatment, with significant improvements noted in the zygomatic area. The mean erythema area decreased by 49.3% after 90 days. One case with acne scarring showed visible improvement in scar appearance, skin tone, and texture. Moreover, 0.10 mg/mL RhCol‐III solution significantly reduced TNF‐α and IL‐6 levels in vitro by up to 47.75% and 44.96%, respectively.

Conclusion

RhCol‐III solution injections effectively reduced facial erythema and have the potential to improve acne scarring via reduction in the extent of PIH in this series of Chinese cases. The treatment was well‐tolerated, with no significant adverse effects. These findings suggest RhCol‐III solution as a promising therapeutic option for skin repair and inflammation reduction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acne VulgarisErythemaCicatrixHyperpigmentationHumansFemaleAdultInjections, IntradermalMaleYoung AdultTreatment OutcomeInterleukin-6Recombinant ProteinsTumor Necrosis Factor-alphaChinaFaceCosmetic TechniquesEast Asian People

Stichwörter der Autor:innen

Chinese populationacne scarringfacial erythemarecombinant type III humanized collagen solution

Substanzen

Interleukin-6Recombinant ProteinsTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Department of Plastic Surgery, Chingho Medical Center, Shanghai, China.
  • L'Oréal Research & Innovation China, Advanced Research, Shanghai, China.
  • L'Oréal Dermatological Beauty China, Skinceuticals, Shanghai, China.
  • Department of Plastic Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Förderung

  • Funding by L'Oreal China was provided exclusively for the in vitro testing described in this article.

Zitieren

APA

Duan, X., Ding, C., Wu, J., Bao, W., Gao, Y., Liu, F., & Cai, W. (2025). Recombinant Type III Humanized Collagen Solution for Injection Promotes Skin Repair in Chinese Population: A Case Series. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70226

Vancouver

Duan X, Ding C, Wu J, Bao W, Gao Y, Liu F, et al. Recombinant Type III Humanized Collagen Solution for Injection Promotes Skin Repair in Chinese Population: A Case Series. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70226

BibTeX
@article{Duan2025,
  author = {Duan, Xiaoguang and Ding, Chunmei and Wu, Jiewei and Bao, Weiwei and Gao, Yu and Liu, Fei and Cai, Wei},
  title = {Recombinant Type III Humanized Collagen Solution for Injection Promotes Skin Repair in Chinese Population: A Case Series},
  journal = {Journal of Cosmetic Dermatology},
  year = {2025},
  doi = {10.1111/jocd.70226}
}
Kostenlos starten →